Bydureon fails to outperform Victoza in diabetes study

03/3/2011 | Bloomberg

Alkermes and Amylin Pharmaceuticals' once-weekly injectable Bydureon failed during a study to outperform or match Novo Nordisk's FDA-approved Victoza, a once-daily injection, in lowering the level of blood sugar in Type 2 diabetics. "We didn't hit the primary endpoint, but the results do actually reinforce the fact that [Bydureon] has a very robust effect," said Amylin CEO Dan Bradbury.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX